Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 9,747,000 | 10,091,000 | 10,410,000 | 11,257,000 | 11,895,000 |
| Cost of Goods | 4,331,000 | 4,593,000 | 4,629,000 | 4,933,000 | 4,987,000 |
| Gross Profit | 5,416,000 | 5,498,000 | 5,781,000 | 6,324,000 | 6,908,000 |
| Operating Expenses | 3,907,000 | 4,194,000 | 4,011,000 | 3,948,000 | 3,996,000 |
| Operating Income | 1,509,000 | 1,304,000 | 1,770,000 | 2,376,000 | 2,912,000 |
| Interest Expense | 153,000 | 154,000 | 141,000 | 132,000 | 131,000 |
| Other Income | 206,000 | 170,000 | 129,000 | 108,000 | 95,000 |
| Pre-tax Income | 1,562,000 | 1,320,000 | 1,758,000 | 2,352,000 | 2,876,000 |
| Income Tax | 244,000 | 287,000 | 323,000 | 334,000 | 429,000 |
| Net Income Continuous | 1,318,000 | 1,033,000 | 1,435,000 | 2,018,000 | 2,447,000 |
| Net Income | $1,318,000 | $1,033,000 | $1,435,000 | $2,018,000 | $2,447,000 |
| EPS Basic Total Ops | 0.75 | 0.59 | 0.82 | 1.15 | 1.38 |
| EPS Basic Continuous Ops | 0.76 | 0.60 | 0.82 | 1.15 | 1.39 |
| EPS Diluted Total Ops | 0.75 | 0.59 | 0.81 | 1.14 | 1.37 |
| EPS Diluted Continuous Ops | 0.75 | 0.59 | 0.81 | 1.14 | 1.38 |
| EBITDA(a) | $2,315,000 | $2,111,000 | $2,585,000 | $3,198,000 | $3,735,000 |